"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2020/112788 A1,162-219-373-903-589,2020-06-04,2020,US 2019/0063271 W,2019-11-26,US 201862771985 P,2018-11-27,DRUG DELIVERY AND BIOMARKER ACCESS DEVICES,"This document describes devices for in vivo drug testing in the brain. This document also describes implantable devices for long-term drug delivery to the brain parenchyma, and for access to biomarkers from the parenchyma.",MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,,https://lens.org/162-219-373-903-589,Patent Application,yes,4,0,5,5,0,A61M5/00;;A61M5/14276;;A61M5/148;;A61M5/16881;;A61M5/16809;;A61M2202/0014;;A61B5/14528;;A61B5/6852;;A61B5/6868;;A61B5/4839;;A61B5/4064;;A61M37/00;;A61B10/0045;;A61B2010/0077;;A61B5/14528;;A61B10/0045;;A61B2010/0077;;A61M5/14276;;A61M5/152;;A61M5/16813;;A61M25/0029;;A61M2210/0693,F15C1/04;;F15C1/02;;F16K49/00,,0,0,,,,PENDING
2,GB,A,GB 1281644 A,120-755-542-977-710,1972-07-12,1972,GB 597170 A,1970-02-07,GB 597170 A,1970-02-07,IMPROVEMENTS IN OR RELATING TO CLAMPS FOR STRUCTURAL FRAMEWORKS,"1281644 Clamps MILLS SCAFFOLD CO Ltd 19 April 1971 [7 Feb 1970] 5971/70 Headings E2A and E2B A clamp for connecting a framework element to a framework member 11 having locating openings 18, incorporates frictional gripping means, i.e. clamping jaws 20, 21, for securing the clamp frictionally to the member and a locating projection 27 mounted thereon for movement relative to the clamp. The projection, in a first operative position, is adapted to engage in one of the openings 18 to positively locate the clamp against movement relative to the member along the length thereof and in a second inoperative position, while still mounted on the clamp, the projection is disposed such that the clamp is secured to the member by the frictional gripping means. As shown, the jaws 20, 21 have lugs 20a, 21a connected by a hinge pin 22 and are drawn to a clamping position by a bolt and nut 23, 24; each jaw carries a tapered spigot 25 for reception in a correspondingly shaped socket 17 of a framework element 14. The projection 27 is pivotable about the pin 22. In modifications, a pair of clamps 19, 32, Fig. 5, are connected by a swivel connection 31 to allow two framework members 11, 34 to be connected at an angle to one another, or welded together, or the jaws 21, 33 of the two clamps are integrally formed in one piece.",MILLS SCAFFOLD CO LTD,BURNS TERENCE JOHN,,https://lens.org/120-755-542-977-710,Granted Patent,no,0,0,1,1,0,E04G7/02,E04G7/02,E2A AE14U         AE14;;E2B B13E          B13E;;E2B B4B4B1        B4B4;;E2B B4J1          B4B4;;E2B B4J3          B4B4;;F2M ME            ME;;F2M M202          ME;;F2M M231          ME;;F2M M232          ME;;F2M M247          ME;;F2M M273          ME,0,0,,,,EXPIRED
3,EP,A4,EP 3887685 A4,190-883-822-737-290,2022-03-09,2022,EP 19889753 A,2019-11-26,US 201862771985 P;;US 2019/0063271 W,2018-11-27,DRUG DELIVERY AND BIOMARKER ACCESS DEVICES,,MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,,https://lens.org/190-883-822-737-290,Search Report,no,2,0,5,5,0,A61M5/00;;A61M5/14276;;A61M5/148;;A61M5/16881;;A61M5/16809;;A61M2202/0014;;A61B5/14528;;A61B5/6852;;A61B5/6868;;A61B5/4839;;A61B5/4064;;A61M37/00;;A61B10/0045;;A61B2010/0077;;A61B5/14528;;A61B10/0045;;A61B2010/0077;;A61M5/14276;;A61M5/152;;A61M5/16813;;A61M25/0029;;A61M2210/0693,F15C1/04;;A61B10/00;;A61M37/00;;F15C1/02;;F16K49/00,,0,0,,,,ACTIVE
4,US,A1,US 2021/0378641 A1,024-797-760-791-848,2021-12-09,2021,US 201917289092 A,2019-11-26,US 201917289092 A;;US 201862771985 P;;US 2019/0063271 W,2018-11-27,DRUG DELIVERY AND BIOMARKER ACCESS DEVICES,"This document describes devices for in vivo drug testing in the brain. This document also describes implantable devices for long-term drug delivery to the brain parenchyma, and for access to biomarkers from the parenchyma.",MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (2019-01-11),https://lens.org/024-797-760-791-848,Patent Application,yes,0,1,5,5,0,A61M5/00;;A61M5/14276;;A61M5/148;;A61M5/16881;;A61M5/16809;;A61M2202/0014;;A61B5/14528;;A61B5/6852;;A61B5/6868;;A61B5/4839;;A61B5/4064;;A61M37/00;;A61B10/0045;;A61B2010/0077;;A61B5/14528;;A61B10/0045;;A61B2010/0077;;A61M5/14276;;A61M5/152;;A61M5/16813;;A61M25/0029;;A61M2210/0693,A61B10/00;;A61M5/142;;A61M5/152;;A61M5/168;;A61M25/00,,0,0,,,,PENDING
5,WO,A1,WO 2022/240583 A1,165-016-315-798-257,2022-11-17,2022,US 2022/0026434 W,2022-04-27,US 202163187726 P,2021-05-12,METHODS AND MATERIALS FOR TREATING CANCER,"This document provides methods and materials for treating a mammal (e.g., a human) having cancer (e.g., a central nervous system (CNS) cancer such as a latent CNS cancer). For example, one or more inhibitors of a B-cell lymphoma-extra large (Bcl-xL) polypeptide can be administered to a mammal (e.g., a human) having a CNS cancer to treat the mammal.",MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,,https://lens.org/165-016-315-798-257,Patent Application,yes,2,0,1,1,3,A61P35/00;;A61P25/00;;A61K45/06;;C12N15/113;;C12N2310/14;;C12N2310/20;;C12N2320/31;;A61K31/428;;A61K31/495;;A61K31/497,A61P35/00;;A61K38/17;;A61P25/00;;G01N33/574,,0,0,,,,PENDING
6,EP,A1,EP 3887685 A1,131-180-446-674-378,2021-10-06,2021,EP 19889753 A,2019-11-26,US 201862771985 P;;US 2019/0063271 W,2018-11-27,DRUG DELIVERY AND BIOMARKER ACCESS DEVICES,,MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,,https://lens.org/131-180-446-674-378,Patent Application,yes,0,0,5,5,0,A61M5/00;;A61M5/14276;;A61M5/148;;A61M5/16881;;A61M5/16809;;A61M2202/0014;;A61B5/14528;;A61B5/6852;;A61B5/6868;;A61B5/4839;;A61B5/4064;;A61M37/00;;A61B10/0045;;A61B2010/0077;;A61B5/14528;;A61B10/0045;;A61B2010/0077;;A61M5/14276;;A61M5/152;;A61M5/16813;;A61M25/0029;;A61M2210/0693,F15C1/04;;F15C1/02;;F16K49/00,,0,0,,,,ACTIVE
7,EP,B1,EP 3887685 B1,195-484-450-240-788,2023-08-16,2023,EP 19889753 A,2019-11-26,US 201862771985 P;;US 2019/0063271 W,2018-11-27,DRUG DELIVERY AND BIOMARKER ACCESS DEVICES,,MAYO FOUND MEDICAL EDUCATION & RES,BURNS TERENCE C,,https://lens.org/195-484-450-240-788,Granted Patent,yes,6,0,5,5,0,A61M5/00;;A61M5/14276;;A61M5/148;;A61M5/16881;;A61M5/16809;;A61M2202/0014;;A61B5/14528;;A61B5/6852;;A61B5/6868;;A61B5/4839;;A61B5/4064;;A61M37/00;;A61B10/0045;;A61B2010/0077;;A61B5/14528;;A61B10/0045;;A61B2010/0077;;A61M5/14276;;A61M5/152;;A61M5/16813;;A61M25/0029;;A61M2210/0693,F15C1/04;;A61B10/00;;A61M37/00;;F15C1/02;;F16K49/00,,0,0,,,,ACTIVE
8,GB,A,GB 2118278 A,056-887-526-657-00X,1983-10-26,1983,GB 8307743 A,1983-03-21,GB 8307743 A;;GB 8210752 A,1982-04-13,Valve or tap,"A valve or tap includes an occluding member (22) of an elastic material and acted on by a push rod (30) extending within it so that it can close an exit port (18) at one end of a chamber in which it is located. So that the occluding member (22) is not caused to vibrate when acted upon by liquid entering the chamber through an entry port 14 in its side wall, the occluding member is surrounded by a sleeve element (36), the latter having a plurality of radial ports through which the liquid can flow so that the occluding member is pressure balanced. <IMAGE>",BRITISH SYPHON IND LTD,BURNS TERENCE;;BLACKSHAW JAMES,,https://lens.org/056-887-526-657-00X,Patent Application,no,6,0,2,2,0,F16K7/20,F16K7/20,F2V VW15          VW15;;U1S S1104;;U1S S1111,0,0,,,,DISCONTINUED
9,GB,A,GB 2117094 A,024-013-326-486-80X,1983-10-05,1983,GB 8306076 A,1983-03-04,GB 8306076 A;;GB 8208344 A,1982-03-22,Flow restrictor for beer line,"A flow restrictor for a beer line has a frusto-conical plug member (10) adjustably located in a frusto-conical flow passage in a body part. So that the flow restrictor will be effective over a wide range of temperature and pressure and rate of flow, the plug member (10) has at its wider end a circumferential groove (44) from which a plurality of inclined holes (46) communicate with a central outlet flow passage (48) through a tail end (24) of the plug member. <IMAGE>",BRITISH SYPHON IND LTD,BURNS TERENCE;;BLACKSHAW JAMES,,https://lens.org/024-013-326-486-80X,Patent Application,no,5,9,2,2,0,B67D1/12;;B67D2001/1494;;F16K1/385,B67D1/12;;B67D1/14;;F16K1/38,F2V VP11          VP11;;U1S S1111,0,0,,,,DISCONTINUED
10,DE,A1,DE 2316469 A1,137-264-059-922-93X,1974-02-21,1974,DE 2316469 A,1973-04-03,GB 3725672 A,1972-08-10,GERAET ZUR DOSIERTEN ABGABE VON FLUESSIGKEITEN,,MILLS BROTHERS SHEFFIELD LTD,BURNS TERENCE;;COLLEY HARRY RICHARDSON,,https://lens.org/137-264-059-922-93X,Patent Application,no,0,0,2,2,0,B67D3/0003;;G01F11/32,B67D3/00;;G01F11/32,,0,0,,,,DISCONTINUED
11,AU,A,AU 1972/047959 A,166-118-926-367-900,1974-04-26,1974,AU 1972/047959 A,1972-10-19,GB 3725672 A,1972-08-10,ELECTRICALLY CONTROLLED LIQUID DISPENSING APPARATUS,,MILLS BROTHERS SHEFFIELD LTD,BURNS TERENCE;;COLLEY HARRY RICHARDSON,,https://lens.org/166-118-926-367-900,Patent Application,no,0,0,2,2,0,B67D3/0003;;G01F11/32,B67D3/00;;G01F11/32,,0,0,,,,DISCONTINUED
12,CN,C,CN 1266093 C,050-889-670-063-629,2006-07-26,2006,CN 03803510 A,2003-02-06,GB 0203058 A,2002-02-09,Production of olefins,,BP CHEM INT LTD,TERENCE BURNS ANDREW LINDSAY G,INEOS COMMERCIAL SERVICES UK LIMITED (2014-05-30);;O AND D TRADING COMPANY LTD. (2009-04-03);;INEOS EUROPE AG (2014-05-30);;INNOVENE EUROP LTD (2009-05-13),https://lens.org/050-889-670-063-629,Granted Patent,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/02;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22;;C10G27/04,,0,0,,,,EXPIRED
13,AT,T1,AT E439838 T1,062-790-590-970-806,2009-09-15,2009,AT 99956491 T,1999-09-24,US 10233498 P;;US 9922163 W,1998-09-29,RADIOMARKIERTE NEUROKININ-1 REZEPTOR ANTAGONISTEN,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H;;GIBSON RAYMOND;;HAMILL TERENCE,,https://lens.org/062-790-590-970-806,Granted Patent,no,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,0,0,,,,EXPIRED
14,AT,T1,AT E549921 T1,118-872-055-731-597,2012-04-15,2012,AT 06815187 T,2006-09-25,US 72178205 P;;US 2006/0036989 W,2005-09-29,RADIOAKTIV MARKIERTE GLYCINTRANSPORTER-HEMMER,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;HAMILL TERENCE;;LINDSLEY CRAIG,,https://lens.org/118-872-055-731-597,Granted Patent,no,0,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,,,0,0,,,,ACTIVE
15,AT,T1,AT E421964 T1,107-802-224-795-397,2009-02-15,2009,AT 02750193 T,2002-07-19,US 30749901 P,2001-07-24,RADIOAKTIV MARKIERTE ANTAGONISTEN DES NEUROPEPTID Y Y5-REZEPTORS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS H;;GIBSON RAYMOND;;HAMILL TERENCE;;FUKAMI TAKEHIRO,,https://lens.org/107-802-224-795-397,Granted Patent,no,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,0,0,,,,EXPIRED
16,WO,A2,WO 2007/041025 A2,030-966-681-390-212,2007-04-12,2007,US 2006/0036989 W,2006-09-25,US 72178205 P,2005-09-29,RADIOLABELED GLYCINE TRANSPORTER INHIBITORS,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK & CO INC;;BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,,https://lens.org/030-966-681-390-212,Patent Application,yes,2,9,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A61K51/00,,3,3,111-443-227-518-259;;190-712-157-525-370;;021-532-872-894-670,9861038;;10.1073/pnas.95.26.15730;;pmc28112;;10.1523/jneurosci.23-20-07586.2003;;12930797;;pmc6740762;;10.1002/jlcr.453,"BERGERON R ET AL., PNAS USA, vol. 95, 1998, pages 15730;;KINNEY G ET AL., J. NEUROSCI., vol. 23, 2003, pages 7586;;RAVERT ET AL., JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 44, 2001, pages 241 - 246",PENDING
17,CO,A2,CO 5601044 A2,089-762-388-617-680,2006-01-31,2006,CO 04073372 A,2004-07-29,GB 0203058 A,2002-02-09,PROCEDIMIENTO PARA LA PRODUCCION DE OLEFINAS,"1.- Procedimiento para la producción de una mono-olefina a partir de un material de alimentación que comprende un hidrocarburo parafínico, caracterizado porque comprende: a) quemar parcialmente, a una presión de, por lo menos 15 bares relativos, una mezcla de la alimentación hidrocarbonada y de un gas que contiene oxígeno molecular en contacto con un catalizador capaz de soportar la combustión más allá del límite de inflamabilidad normal rico en combustible en donde tales componentes se hacen reaccionar para formar un producto que comprende una o más mono-olefinas, monóxido de carbono e hidrógeno; y b) recuperar dicha o dichas olefinas.2.- Procedimiento según la reivindicación 1, caracterizado porque la etapa (b) comprende separar el producto de la etapa (a) en una corriente que comprende monóxido de carbono e hidrógeno y en una corriente que comprende una o más olefinas y recuperar dicha o dichas olefinas.3.- Procedimiento según la reivindicación 2, caracterizado porque comprende la etapa de (c) pasar la corriente que comprende monóxido de carbono e hidrógeno separada en la etapa (b) a un reactor Fischer- Tropsch que contiene un catalizador Fischer-Tropsch en donde al menos parte de dicha corriente se convierte a hidrocarburos, y recuperar a continuación al menos una parte del producto hidrocarbonado.4.- Procedimiento según la reivindicación 3, caracterizado porque el producto producido en la etapa (a) comprende una o más mono-olefinas, monóxido de carbono, hidrógeno y metano y la etapa (b) separa el producto de la etapa (a) en una corriente que comprende monóxido de carbono, hidrógeno y metano, la cual se pasa entonces al reactor Fischer- Tropsch de la etapa (c).5.- Procedimiento según cualquiera de las reivindicaciones anteriores, caracterizado porque el producto producido en la etapa (a) comprende dióxido de carbono y porque antes de la etapa (b), el dióxido de carbono se separa de la corriente de producto.",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/089-762-388-617-680,Patent Application,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,DISCONTINUED
18,CA,A1,CA 2474741 A1,152-147-990-857-183,2003-08-14,2003,CA 2474741 A,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,PRODUCTION OF OLEFINS,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocabon which process comprises a) partially combusting at a pressure of at least (15) barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/152-147-990-857-183,Patent Application,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,EXPIRED
19,EA,B1,EA 007344 B1,018-791-031-758-998,2006-08-25,2006,EA 200400990 A,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,PRODUCTION OF OLEFINS,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocarbon which process comprises a) partially combusting at a pressure of at least (15) bar a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/018-791-031-758-998,Granted Patent,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/02;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22;;C10G27/04,,0,0,,,,EXPIRED
20,EP,A4,EP 1119356 A4,051-540-461-874-85X,2008-01-09,2008,EP 99956491 A,1999-09-24,US 9922163 W;;US 10233498 P,1998-09-29,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-07-13)",https://lens.org/051-540-461-874-85X,Search Report,no,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,5,4,039-356-005-684-126;;003-438-019-662-780;;119-989-385-381-986;;074-159-295-991-744,pmc1909155;;8719790;;10.1111/j.1476-5381.1995.tb15118.x;;8876035;;10.1016/0167-0115(96)00071-7;;9458530;;10.1007/s005200050125;;8841890;;10.1016/0891-0618(96)00130-5,"FASTH K J ET AL: ""Brain uptake and receptor binding of two 11C-labelled selective high affinity NK1-antagonists, GR203040 and GR205171"", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, JOHN WILEY, CHICHESTER, GB, vol. 40, December 1997 (1997-12-01), pages 665 - 667, XP009091925, ISSN: 0362-4803;;GARDNER C J ET AL: ""THE BROAD-SPECTRU ANTI-EMETIC ACTIVITY OF THE NOVEL NON-PEPTIDE TACHYKININ NK1 RECEPTOR ANTAGONIST GR203040"", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 116, no. 8, 1995, pages 3158 - 3163, XP000575088, ISSN: 0007-1188;;GARDNER ET AL: ""GR 205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity"", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 65, no. 1, 1996, pages 45 - 53, XP002297280, ISSN: 0167-0115;;HERRSTEDT J: ""Antiemetic research: a look to the future"", SUPPORTIVE CARE IN CANCER, vol. 6, no. 1, December 1997 (1997-12-01), pages 8 - 12, XP002458181;;LAPORTE A M, DOYEN C, NEVO I T, CHAUVEAU J, HAUW J J, HAMON M: ""Autoradiographic mapping of serotonin 5-HT1A, 5-HT1D, 5-HT2A and 5-HT3 receptors in the aged human spinal cord"", JOURNAL OF CHEMICAL NEUROANATOMY, vol. 11, 1996, pages 67 - 75, XP002458182",EXPIRED
21,CA,C,CA 2474741 C,115-899-570-426-563,2012-04-03,2012,CA 2474741 A,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,PRODUCTION OF OLEFINS,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocabon which process comprises a) partially combusting at a pressure of at least (15) barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/115-899-570-426-563,Granted Patent,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/02;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22;;C10G27/04,,0,0,,,,EXPIRED
22,US,A1,US 2005/0020868 A1,137-289-724-199-843,2005-01-27,2005,US 50284604 A,2004-07-29,GB 0300498 W;;GB 0203058 A,2002-02-09,Production of olefins,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocabon which process comprises a) partially combusting at a pressure of at least (15) barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,INEOS COMMERCIAL SERVICES UK LIMITED (2011-06-01);;INEOS EUROPE AG (2013-09-01);;BP CHEMICALS LIMITED (2004-08-08),https://lens.org/137-289-724-199-843,Patent Application,yes,0,4,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07B61/00;;C07C2/00;;C07C5/48;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,585/658,0,0,,,,EXPIRED
23,AU,A1,AU 2003/215714 A1,188-236-573-750-466,2003-09-02,2003,AU 2003/215714 A,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,PRODUCTION OF OLEFINS,,INEOS EUROPE LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,INEOS EUROPE LIMITED (2006-09-21),https://lens.org/188-236-573-750-466,Patent Application,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,DISCONTINUED
24,EP,B1,EP 1119356 B1,001-827-939-288-302,2009-08-19,2009,EP 99956491 A,1999-09-24,US 9922163 W;;US 10233498 P,1998-09-29,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-07-13)",https://lens.org/001-827-939-288-302,Granted Patent,yes,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,A61K31/445;;C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,1,1,030-770-781-720-536,15564148;;10.1016/j.mibio.2004.08.001,"SOLIN O. ET AL: ""Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ)"", MOLECULAR IMAGING AND BIOLOGY, vol. 6, no. 6, 2004, pages 373 - 384, XP004653689, DOI: doi:10.1016/j.mibio.2004.08.001",EXPIRED
25,AU,A,AU 2000/063365 A,031-302-461-448-51X,2001-01-09,2001,AU 2000/063365 A,2000-06-22,US 14053699 P;;US 0017185 W,1999-06-23,Radiolabeled farnesyl-protein transferase inhibitors,,MERCK & CO INC,BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,,https://lens.org/031-302-461-448-51X,Patent Application,no,0,0,3,3,0,A61K51/0459;;A61K51/0459;;C12Q1/48;;C12Q1/48;;C07D233/64;;C07D233/64,A61K51/04;;C07D233/54;;C12Q1/48,,0,0,,,,DISCONTINUED
26,TW,A,TW 200302868 A,033-793-605-066-337,2003-08-16,2003,TW 92102559 A,2003-02-07,GB 0203058 A,2002-02-09,Production of olefins,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocarbon which process comprises (a) partially combusting at a pressure of at least 15 barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and (b) recovering the one or more olefin(s).",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/033-793-605-066-337,Patent of Addition,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C10G11/22;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00,,0,0,,,,EXPIRED
27,NO,L,NO 20043760 L,157-158-242-049-952,2004-11-09,2004,NO 20043760 A,2004-09-08,GB 0203058 A;;GB 0300498 W,2002-02-09,Fremgangsmate til fremstilling av olefiner,,BP CHEM INT LTD,WOODFIN WILLIAM TERENCE;;GRIFFITHS DAVID CHARLES;;BURNS ANDREW LINDSAY,,https://lens.org/157-158-242-049-952,Abstract,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,DISCONTINUED
28,US,B2,US 7518027 B2,172-817-817-306-068,2009-04-14,2009,US 50284604 A,2004-07-29,GB 0300498 W;;GB 0203058 A,2002-02-09,Production of olefins,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocabon which process comprises a) partially combusting at a pressure of at least (15) barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",INNOVENE EUROP LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,INEOS COMMERCIAL SERVICES UK LIMITED (2011-06-01);;INEOS EUROPE AG (2013-09-01);;BP CHEMICALS LIMITED (2004-08-08),https://lens.org/172-817-817-306-068,Granted Patent,yes,14,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/327;;C07B61/00;;C07C5/48;;C07C2/00;;C07C5/333;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,585/658;;585/651;;585/652;;585/653;;585/660;;585/661;;585/662;;585/663,0,0,,,,INACTIVE
29,WO,A1,WO 2000/018403 A1,131-838-437-908-193,2000-04-06,2000,US 9922163 W,1999-09-24,US 10233498 P,1998-09-29,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC;;BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,,https://lens.org/131-838-437-908-193,Patent Application,yes,0,7,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,5,0,,,"DATABASE CA ARMOUR ET AL.: ""Preparation of 3 (tetrazolyl)alkyl)phenyl)methyl)amino)piperidine tachykinin antagonists"", XP002966448;;DATABASE CA TOMIYOSHI ET AL.: ""Positron emission tomography for evaluation of dopaminergic function using a neurotransmitter analog L-18F-m-tyrosin in monkey brain"", XP002966449;;DATABASE CA OOSAKI ET AL.: ""Method for producing fluorine radioisotope-labeled organic compound (18F)-2-fluoro-2-deoxy-d-glucose"", XP002966450;;DATABASE CA GIBLIN ET AL.: ""Preparation of 3-(tetrazolylbenzylamino)-2-phenylpiperidines as neurokinin antagonists"", XP002966451;;GREENE T.W., Protective groups in organic synthesis, John Wiley & Sons, page 232, 1982.",PENDING
30,CN,A,CN 1630625 A,171-099-826-684-845,2005-06-22,2005,CN 03803510 A,2003-02-06,GB 0203058 A,2002-02-09,Production of olefins,,BP CHEM INT LTD,LINDSAY BURNS ANDREW;;CHARLES GRIFFITHS DAVID;;TERENCE WOODFIN WILLIAM,INEOS COMMERCIAL SERVICES UK LIMITED (2014-05-30);;O AND D TRADING COMPANY LTD. (2009-04-03);;INEOS EUROPE AG (2014-05-30);;INNOVENE EUROP LTD (2009-05-13),https://lens.org/171-099-826-684-845,Patent Application,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,EXPIRED
31,US,B1,US 6458935 B1,182-767-627-484-883,2002-10-01,2002,US 66863700 A,2000-06-12,US 66863700 A;;US 14053699 P,1999-06-23,Radiolabeled farnesyl-protein transferase inhibitors,"
    The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase. 
",MERCK & CO INC,BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,MERCK SHARP & DOHME CORP (2000-05-25),https://lens.org/182-767-627-484-883,Granted Patent,yes,19,51,3,3,0,A61K51/0459;;A61K51/0459;;C12Q1/48;;C12Q1/48;;C07D233/64;;C07D233/64,A61K51/04;;C07D233/54;;C12Q1/48,534/10;;544/370;;558/414,13,8,087-368-627-163-527;;001-323-085-306-423;;077-023-595-484-492;;077-351-256-647-106;;046-383-404-457-876;;001-556-683-663-233;;087-834-161-885-514;;089-979-181-759-179,8463291;;10.1016/s0021-9258(18)52998-7;;1874715;;10.1016/s0021-9258(18)98441-3;;7890759;;10.1074/jbc.270.11.6221;;10.1038/nm0895-792;;7585182;;10.1073/pnas.91.19.9141;;8090782;;pmc44763;;1567835;;10.1021/bi00130a010;;7585592;;10.1126/science.8316833;;8316833,"J. Labelled Cpd. Radiopharm., vol. 42, Suppl. 1 (1999), pp. S204-S206, by W-S Eng, et al.;;J. of Biol. Chem., vol. 268, No. 11, pp. 7617-7620 (1993), by Gibbs, et al.;;J. of Biol. Chem., vol. 266, No. 24, pp. 15575-15578 (1991), by Goldstein, et al.;;Exp. Opin. Ther. Patents, vol. 5, No. 12, pp. 1269-1285 (1995), by Graham.;;J. of Biol. Chem., vol. 270, No. 11, pp. 6221-6226 (1995), by James, et al.;;Nature Medicine, vol. 1, No. 8, pp. 792-797 (1995), by Kohl, et al.;;Proc. Natl. Acad. Sci. USA, Med. Sciences, vol. 91, pp. 9141-9145 (1994), by Kohl, et al.;;Biochemistry, vol. 31, pp. 3800-3807 (1992), by Pompliano.;;Cancer Research, vol. 55, pp. 5302-5309 (1995), by Sepp-Lorenzino, et al.;;Exp. Opin. Ther. Patents, vol. 6, No. 12, pp. 1295-1304 (1996), by Graham, et al.;;Science, vol. 260, pp. 1934-1937 (1993), by Kohl, et al.;;J. of Labelled Compounds & Radiopharm., vol. 42, S30-32 (1999), by T. G. Hamill, et al.;;J. of Nuclear Med., vol. 40, No. 5, Suppl. 99P (1999), No. 400 by R. E. Gibson, et al.",EXPIRED
32,DE,D1,DE 60333439 D1,019-915-945-798-361,2010-09-02,2010,DE 60333439 T,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,HERSTELLUNG VON OLEFINEN,,INEOS EUROPE LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/019-915-945-798-361,Granted Patent,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/02;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22;;C10G27/04,,0,0,,,,EXPIRED
33,WO,A1,WO 2000/078363 A1,017-607-523-356-654,2000-12-28,2000,US 0017185 W,2000-06-22,US 14053699 P,1999-06-23,RADIOLABELED FARNESYL-PROTEIN TRANSFERASE INHIBITORS,"The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.",MERCK & CO INC;;BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,,https://lens.org/017-607-523-356-654,Patent Application,yes,0,0,3,3,0,A61K51/0459;;A61K51/0459;;C12Q1/48;;C12Q1/48;;C07D233/64;;C07D233/64,A61K51/04;;C07D233/54;;C12Q1/48,,1,0,,,"ENG W.S. ET AL.: ""Preparation of (C-11)-labeled radiotracers for imaging farnesyl transferase distribution and enzyme occupancy"", J. LABELLED CPD. RADIOPHARM.,, vol. 42. SUPPL. 1, 1999, pages S204 - S206, XP002931334",PENDING
34,CA,A1,CA 2343106 A1,103-142-966-209-936,2000-04-06,2000,CA 2343106 A,1999-09-24,US 10233498 P;;US 9922163 W,1998-09-29,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,,https://lens.org/103-142-966-209-936,Patent Application,no,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,0,0,,,,DISCONTINUED
35,EP,A1,EP 1119356 A1,185-303-134-831-123,2001-08-01,2001,EP 99956491 A,1999-09-24,US 9922163 W;;US 10233498 P,1998-09-29,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-07-13)",https://lens.org/185-303-134-831-123,Patent Application,yes,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,A61K31/445;;C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,0,0,,,,EXPIRED
36,US,B1,US 6241964 B1,107-318-836-605-801,2001-06-05,2001,US 40782299 A,1999-09-28,US 40782299 A;;US 10233498 P,1998-09-29,F-18 radiolabeled neurokinin-1 receptor antagonists,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;HAMILL TERENCE G;;GIBSON RAYMOND E,MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/107-318-836-605-801,Granted Patent,yes,3,41,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,424/1.89;;546/210;;546/223;;435/7.1;;436/804,5,0,,,"Mishani, E. et al., Synthesis and evaluation of a fluorine-18 labeled NK-1 antagonist, Jour. of Labeled Compounds and Radiopharmaceuticals, vol. 40, pp. 653-655, Dec. 1997.*;;Casdata-CA 125:4529, Tomiyoshi, et al, ""positron emission tomography for evaluation of dopaminergic function using a neurotransmitter analog L-18F-m-tyrosin in monkey brain"" Bioimages vol. 4. No. 1, pp. 1-7 (1996).;;Casdata-CA 126:118149, Oosaki, et al, ""method for producing fluorine radioisotope-Ibeled organic compound [18F]-2-fluoro-2-deoxy-d-glucose"" (1996) JP 08325169, see entire abstract.;;Casdata-CA 126:18876, Giblin et al, ""Preparation of 3-(tetrazolylbenzylamino)-2-phenylpiperidines as neurokinin antagonists"" (1996) WO 96/29326, see abstract and RN180574-25-8.;;Greene, T.W., Protective groups in organic synthesis, John Wiley & sons, p. 232 (1982).",EXPIRED
37,EP,A1,EP 1472203 A1,096-884-566-082-033,2004-11-03,2004,EP 03737363 A,2003-02-06,GB 0300498 W;;GB 0203058 A,2002-02-09,PRODUCTION OF OLEFINS,,BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,"INEOS EUROPE LIMITED (2007-03-21);;INEOS COMMERCIAL SERVICES UK LIMITED, GB (2014-04-10);;INNOVENE EUROPE LIMITED (2006-03-22);;O & D TRADING LIMITED (2005-07-13);;INEOS EUROPE AG, CH (2015-01-27)",https://lens.org/096-884-566-082-033,Patent Application,yes,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,EXPIRED
38,EP,B1,EP 1472203 B1,181-334-841-299-574,2010-07-21,2010,EP 03737363 A,2003-02-06,GB 0300498 W;;GB 0203058 A,2002-02-09,PRODUCTION OF OLEFINS,,INEOS EUROPE LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,"INEOS EUROPE LIMITED (2007-03-21);;INEOS COMMERCIAL SERVICES UK LIMITED, GB (2014-04-10);;INNOVENE EUROPE LIMITED (2006-03-22);;O & D TRADING LIMITED (2005-07-13);;INEOS EUROPE AG, CH (2015-01-27)",https://lens.org/181-334-841-299-574,Granted Patent,yes,1,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/02;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22;;C10G27/04,,0,0,,,,EXPIRED
39,EP,A4,EP 1942733 A4,015-284-729-881-124,2010-11-10,2010,EP 06815187 A,2006-09-25,US 2006/0036989 W;;US 72178205 P,2005-09-29,RADIOLABELED GLYCINE TRANSPORTER INHIBITORS,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,"MERCK SHARP & DOHME CORP., US (2013-06-18);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-06-18);;SCHERING CORPORATION (2012-08-08);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK  SHARP & DOHME CORP. (2012-10-19);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-06-18)",https://lens.org/015-284-729-881-124,Search Report,no,0,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A01N41/06;;A61K31/18;;A61K31/195;;C07D211/64;;C07D401/04,,1,0,,,No further relevant documents disclosed,ACTIVE
40,EP,B1,EP 1942733 B1,024-838-055-502-738,2012-03-21,2012,EP 06815187 A,2006-09-25,US 2006/0036989 W;;US 72178205 P,2005-09-29,RADIOLABELED GLYCINE TRANSPORTER INHIBITORS,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,"MERCK SHARP & DOHME CORP., US (2013-06-18);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-06-18);;SCHERING CORPORATION (2012-08-08);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK  SHARP & DOHME CORP. (2012-10-19);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-06-18)",https://lens.org/024-838-055-502-738,Granted Patent,yes,2,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A01N41/06;;A61K31/18;;A61K31/195;;C07D211/64;;C07D401/04,,0,0,,,,ACTIVE
41,ES,T3,ES 2382818 T3,187-188-784-743-020,2012-06-13,2012,ES 06815187 T,2006-09-25,US 72178205 P;;US 2006/0036989 W,2005-09-29,Inhibidores de transportadores glicina radiomarcados,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,,https://lens.org/187-188-784-743-020,Granted Patent,no,0,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A01N41/06;;A61K31/18;;A61K31/195;;C07D211/64;;C07D401/04,,0,0,,,,ACTIVE
42,EP,A2,EP 1942733 A2,054-075-858-387-732,2008-07-16,2008,EP 06815187 A,2006-09-25,US 2006/0036989 W;;US 72178205 P,2005-09-29,RADIOLABELED GLYCINE TRANSPORTER INHIBITORS,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK & CO INC,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,"MERCK SHARP & DOHME CORP., US (2013-06-18);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-06-18);;SCHERING CORPORATION (2012-08-08);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME LLC, RAHWAY, US (2022-09-29);;MERCK  SHARP & DOHME CORP. (2012-10-19);;MERCK SHARP  DOHME CORP., RAHWAY, US (2013-06-18)",https://lens.org/054-075-858-387-732,Patent Application,yes,0,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A01N41/06;;A61K31/18;;A61K31/195;;C07D211/64;;C07D401/04,,0,0,,,,ACTIVE
43,DE,D1,DE 69941298 D1,175-397-541-812-98X,2009-10-01,2009,DE 69941298 T,1999-09-24,US 10233498 P;;US 9922163 W,1998-09-29,RADIOMARKIERTE NEUROKININ-1 REZEPTOR ANTAGONISTEN,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US (2010-09-23);;SCHERING CORPORATION, US (2012-12-13)",https://lens.org/175-397-541-812-98X,Granted Patent,no,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,A61K31/445;;C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,0,0,,,,EXPIRED
44,WO,A3,WO 2007/041025 A3,031-775-590-367-425,2007-08-30,2007,US 2006/0036989 W,2006-09-25,US 72178205 P,2005-09-29,RADIOLABELED GLYCINE TRANSPORTER INHIBITORS,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK & CO INC;;BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,,https://lens.org/031-775-590-367-425,Search Report,yes,2,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A61K31/18;;A01N41/06;;A61K31/195,,0,0,,,,PENDING
45,US,A1,US 2009/0269278 A1,063-497-653-629-968,2009-10-29,2009,US 99172705 A,2005-09-29,US 99172705 A;;US 72178205 P;;US 2006/0036989 W,2005-09-29,Radiolabeled Glycine Trasporter Inhibitors,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/063-497-653-629-968,Patent Application,yes,7,6,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,C07D211/96;;A61K51/04;;C12Q1/02,424/1.89;;546/234;;435/29,0,0,,,,ACTIVE
46,AU,A,AU 2000/013091 A,068-427-395-506-620,2000-04-17,2000,AU 2000/013091 A,1999-09-24,US 10233498 P;;US 9922163 W,1998-09-29,Radiolabeled neurokinin-1 receptor antagonists,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G,,https://lens.org/068-427-395-506-620,Patent Application,no,0,0,10,10,0,A61K51/0455;;C07B59/002;;C07B2200/05;;C07D401/12;;Y10S436/804;;C07D401/12;;A61K51/0455;;C07B59/002;;C07B2200/05;;Y10S436/804,C07D403/12;;A61K51/00;;A61K51/04;;C07B59/00;;C07D401/12,,0,0,,,,PENDING
47,WO,A1,WO 2003/066551 A1,137-975-560-503-131,2003-08-14,2003,GB 0300498 W,2003-02-06,GB 0203058 A,2002-02-09,PRODUCTION OF OLEFINS,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocabon which process comprises a) partially combusting at a pressure of at least (15) barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and b) recovering the one or more olefin(s).",BP CHEM INT LTD;;BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/137-975-560-503-131,Patent Application,yes,1,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C07C5/48;;C10G11/22,,0,0,,,,PENDING
48,US,B2,US 7834031 B2,193-459-839-834-739,2010-11-16,2010,US 99172705 A,2005-09-29,US 99172705 A;;US 72178205 P;;US 2006/0036989 W,2005-09-29,Radiolabeled glycine transporter inhibitors,The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;HAMILL TERENCE G;;LINDSLEY CRAIG W,MERCK SHARP & DOHME LLC (2022-04-07);;MERCK SHARP & DOHME CORP (2012-05-02),https://lens.org/193-459-839-834-739,Granted Patent,yes,10,0,9,9,0,A61K51/0455;;C07B59/002;;C07D211/64;;C07D401/04;;C07D211/64;;C07D401/04;;A61K51/0455;;C07B59/002,A61K31/445;;C07D211/06;;C07D401/04,514/318;;546/184;;546/192;;546/207;;546/208;;514/315,0,0,,,,ACTIVE
49,TW,B,TW I287572 B,029-261-748-764-069,2007-10-01,2007,TW 92102559 A,2003-02-07,GB 0203058 A,2002-02-09,Production of olefins,"A process for the production of a mono-olefin from a feedstock comprising a paraffinic hydrocarbon which process comprises (a) partially combusting at a pressure of at least 15 barg a mixture of the hydrocarbon feed and a molecular oxygen-containing gas in contact with a catalyst capable of supporting combustion beyond the normal fuel rich limit of flammability where they are reacted to form a product comprising one or more mono-olefin(s), carbon monoxide and hydrogen and (b) recovering the one or more olefin(s).",INEOS EUROPE LTD,BURNS ANDREW LINDSAY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/029-261-748-764-069,Granted Patent,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00,,0,0,,,,EXPIRED
50,BR,A,BR 0307322 A,069-316-694-148-725,2004-12-28,2004,BR 0307322 A,2003-02-06,GB 0203058 A;;GB 0300498 W,2002-02-09,Processo para produção de olefinas,"""PROCESSO PARA PRODUçãO DE OLEFINAS"". Processo para a produção de uma mono-olefina a partir de um estoque de alimentação que compreende um hidrocarboneto parafínico, processo este que compreende a) queimar parcialmente a uma pressão de pelo menos (1,5) MPa uma mistura da alimentação de hidrocarboneto e de um gás que contém oxigênio molecular em contato com um catalisador capaz de suportar combustão para além do limite normal de combustível rico de inflamabilidade onde são reagidos para formar um produto que compreende uma ou mais mono-olefina(s), monóxido de carbono e hidrogênio e b) recuperar uma ou mais daquela(s) olefina(s).",BP CHEM INT LTD,BURNS ANDREW LINDSAY;;GRIFFIYTHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,INEOS EUROPE LIMITED (GB) (2008-04-08);;OANDD TRADING LIMITED (GB) (2008-03-11);;INNOVENE EUROPE LIMITED (GB) (2008-03-25),https://lens.org/069-316-694-148-725,Patent Application,no,0,0,27,27,0,C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40;;C07C5/48;;C10G27/04;;C10G2/32;;C10G2400/20;;C10G2300/1081;;C07C5/48;;C07C2521/04;;C07C2523/42;;Y02P30/40,C07C5/48;;C07B61/00;;C07C2/00;;C07C11/04;;C07C11/06;;C10G2/00;;C10G11/22,,0,0,,,,DISCONTINUED
51,AT,T1,AT E487479 T1,028-722-159-298-365,2010-11-15,2010,AT 03759348 T,2003-09-19,US 41322302 P;;US 0329707 W,2002-09-24,RADIOAKTIV MARKIERTE NEUROKININ-1-REZEPTOR- ANTAGONISTEN,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND;;HAMILL TERENCE,,https://lens.org/028-722-159-298-365,Granted Patent,no,0,0,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,0,0,,,,EXPIRED
52,ES,T3,ES 2354151 T3,175-074-799-885-733,2011-03-10,2011,ES 03759348 T,2003-09-19,US 41322302 P,2002-09-24,ANTAGONISTAS DEL RECEPTOR DE NEUROQUININA-1 RADIOMARCADOS.,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND;;HAMILL TERENCE,,https://lens.org/175-074-799-885-733,Granted Patent,no,0,0,12,12,0,C07D401/12;;C07D401/12,A61K31/445;;A61K51/00;;C07D401/12,,0,0,,,,EXPIRED
53,EP,B1,EP 1470129 B1,035-000-692-743-403,2009-01-28,2009,EP 02750193 A,2002-07-19,US 0223044 W;;US 30749901 P,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,"MERCK SHARP & DOHME CORP., US (2013-05-15);;126 EAST LINCOLN AVENUE, RAHWAY  NEW JERSEY 07065 (2012-08-02);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-15);;SCHERING CORPORATION, US; MSD K.K., JP (2012-07-13);;KITANOMARU SQUARE 1-13-12 KUDANKITA,CHIYODA-KU TOK (2012-08-02);;MSD K.K., JP (2013-05-15);;BANYU PHARMACEUTICAL CO., LTD. (2010-09-15);;MSD K.K. (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-08-02)",https://lens.org/035-000-692-743-403,Granted Patent,yes,3,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,C07D491/10;;G01T1/161;;A61K49/00;;A61K51/00;;A61K51/04;;A61M36/14;;C07D491/04;;C07D491/107,,1,0,,,"MCNALLY J J ET AL: ""N-Acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagonists of the human neuropeptide Y Y5 receptor"" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 15, 7 August 2000 (2000-08-07), pages 1641-1643, XP004213213 ISSN: 0960-894X",EXPIRED
54,US,A1,US 2004/0192705 A1,197-748-522-069-959,2004-09-30,2004,US 48455104 A,2004-01-22,US 48455104 A;;US 30749901 P;;US 0223044 W,2001-07-24,Radiolabeled neuropeptide y y5 receptor antagonists,"
   The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals. 
",BURNS H. DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,BANYU PHARMACEUTICAL CO. LTD (2002-07-04);;MSD K.K (2011-02-24);;MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/197-748-522-069-959,Patent Application,yes,1,3,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,514/256;;X54423;;424/1.11,0,0,,,,EXPIRED
55,WO,A3,WO 2003/010175 A3,090-553-932-450-314,2004-05-27,2004,US 0223044 W,2002-07-19,US 30749901 P,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD;;BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,,https://lens.org/090-553-932-450-314,Search Report,yes,1,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,0,0,,,,PENDING
56,EP,A2,EP 1470129 A2,151-975-909-474-693,2004-10-27,2004,EP 02750193 A,2002-07-19,US 0223044 W;;US 30749901 P,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,"MERCK SHARP & DOHME CORP., US (2013-05-15);;126 EAST LINCOLN AVENUE, RAHWAY  NEW JERSEY 07065 (2012-08-02);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-15);;SCHERING CORPORATION, US; MSD K.K., JP (2012-07-13);;KITANOMARU SQUARE 1-13-12 KUDANKITA,CHIYODA-KU TOK (2012-08-02);;MSD K.K., JP (2013-05-15);;BANYU PHARMACEUTICAL CO., LTD. (2010-09-15);;MSD K.K. (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-08-02)",https://lens.org/151-975-909-474-693,Patent Application,yes,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,0,0,,,,EXPIRED
57,CA,C,CA 2454228 C,197-772-383-744-511,2011-03-22,2011,CA 2454228 A,2002-07-19,US 30749901 P;;US 0223044 W,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,"The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists of the formula: (see above formula) which can be labeled with a radionuclide selected from the group consisting of: 3H, 11C, 18F, 15O and 13 N; analogs of this compound could be labeled with 1251, 123I, 131I, 75Br, 15O, 13N, 211At, 82Br, 77Br or 76Br; particular antagonists include [11C] trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofurane-1(3H),1'-cyclohexane]-4'-carboxamide and [18F] trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofurane-1(3H),1'-cyclohexane]-4'-carboxamide and pharmaceutically acceptable salts thereof; the antagonists are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.",MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,,https://lens.org/197-772-383-744-511,Granted Patent,no,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,C07D491/048;;G01T1/161;;A61K31/506;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107;;G01N33/566;;G01N33/60,,0,0,,,,EXPIRED
58,DE,D1,DE 60231062 D1,133-506-949-414-287,2009-03-19,2009,DE 60231062 T,2002-07-19,US 30749901 P;;US 0223044 W,2001-07-24,Y Y5-REZEPTORS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS DONALD H;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,"MSD K.K., JP (2012-12-13);;MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US (2010-09-23);;BANYU PHARMACEUTICAL CO., LTD., TOKIO/TOKYO, JP (2010-09-23);;SCHERING CORPORATION, US (2012-12-13)",https://lens.org/133-506-949-414-287,Granted Patent,no,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,C07D491/10;;G01T1/161;;A61K49/00;;A61K51/00;;A61K51/04;;A61M36/14;;C07D491/04;;C07D491/107,,0,0,,,,EXPIRED
59,WO,A2,WO 2003/010175 A2,172-012-056-774-749,2003-02-06,2003,US 0223044 W,2002-07-19,US 30749901 P,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD;;BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,,https://lens.org/172-012-056-774-749,Patent Application,yes,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,0,0,,,,PENDING
60,CA,A1,CA 2454228 A1,077-796-950-226-987,2003-02-06,2003,CA 2454228 A,2002-07-19,US 30749901 P;;US 0223044 W,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC,FUKAMI TAKEHIRO;;HAMILL TERENCE G;;GIBSON RAYMOND E;;BURNS H DONALD,,https://lens.org/077-796-950-226-987,Patent Application,no,0,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,0,0,,,,EXPIRED
61,EP,A4,EP 1470129 A4,066-481-700-501-952,2007-08-01,2007,EP 02750193 A,2002-07-19,US 0223044 W;;US 30749901 P,2001-07-24,RADIOLABELED NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,MERCK & CO INC;;BANYU PHARMA CO LTD,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,"MERCK SHARP & DOHME CORP., US (2013-05-15);;126 EAST LINCOLN AVENUE, RAHWAY  NEW JERSEY 07065 (2012-08-02);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-15);;SCHERING CORPORATION, US; MSD K.K., JP (2012-07-13);;KITANOMARU SQUARE 1-13-12 KUDANKITA,CHIYODA-KU TOK (2012-08-02);;MSD K.K., JP (2013-05-15);;BANYU PHARMACEUTICAL CO., LTD. (2010-09-15);;MSD K.K. (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK SHARP & DOHME CORP. (2012-08-02)",https://lens.org/066-481-700-501-952,Search Report,no,2,0,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,,1,1,097-102-691-528-468,10937714;;10.1016/s0960-894x(00)00311-5,"MCNALLY J J ET AL: ""N-Acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagonists of the human neuropeptide Y Y5 receptor"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 15, 7 August 2000 (2000-08-07), pages 1641 - 1643, XP004213213, ISSN: 0960-894X",EXPIRED
62,US,B2,US 6939966 B2,094-547-305-954-550,2005-09-06,2005,US 48455104 A,2004-01-22,US 48455104 A;;US 30749901 P;;US 0223044 W,2001-07-24,Radiolabeled neuropeptide Y Y5 receptor antagonists,The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.,BANYU PHARMA CO LTD,BURNS H DONALD;;GIBSON RAYMOND E;;HAMILL TERENCE G;;FUKAMI TAKEHIRO,BANYU PHARMACEUTICAL CO. LTD (2002-07-04);;MSD K.K (2011-02-24);;MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/094-547-305-954-550,Granted Patent,yes,2,4,13,13,0,A61K51/0459;;C07B2200/05;;C07D491/04;;C07D491/04;;A61K51/0459;;C07B2200/05,G01T1/161;;A61K51/00;;A61K51/04;;C07D491/04;;C07D491/107,544/331;;546/16;;424/1.81;;424/1.85;;424/1.89;;424/9.2,8,7,003-379-736-486-014;;150-553-349-843-326;;009-487-818-952-775;;174-642-486-577-963;;135-902-609-845-053;;054-215-239-939-616;;026-523-713-145-063,10.1016/0031-9384(91)90490-f;;1658831;;10.1016/s0040-4039(00)93671-2;;10.1016/0040-4020(82)80190-7;;10.1016/s0040-4039(00)86251-6;;10.1016/0040-4039(96)01822-9;;10.1002/cber.19911240939;;10.3987/com-98-8192,"Kalra et al., Phys. & Behavior 50 (1991), p. 5-9, ""Structure-function analysis of stimulation of food intake by neuropeptide Y: Effects of receptor agonists"".;;Gribble et al., Tetrahedron Lett., vol. 21 (1980), pp. 4137-4140, ""Regioselective ortho lithiation of halopyridines"".;;Mallet et al., Tetrahedron, vol. 38 (1982), pp. 3035-3042, ""Reaction de la bromo-3 pyridine avec le diisopropylamidure de lithium . . . "".;;Corey et al., Tetrahedron Lett., vol. 24 (1983), pp. 3291-3294, ""Synthesis of a new series of potent inhibitors of thromboxane A2 biosynthesis"".;;Jones et al., Tetra. Letters, vol. 37 (1996), pp. 8049-8052, ""Pyridine radicals in synthesis: a formal total synthesis of (±)-oxerine"".;;Gribble et al., Heterocycles, vol. 35 (1993), pp. 151-169, ""Regioselective ortho-lithiation of halopyridines . . . "".;;Effenberger et al., Chem. Ber., vol. 124 (1991), pp. 2119-2125, ""Darstellung van didehydropyridinen aus (trimethylsilyl)pyridinen"".;;Miki et al., Heterocycles, vol. 48 (1998), pp. 1593-1597. ""Reaction of 1-benzylindole-2,3-dicarboxylic anhydride with 3-bromo-4-lithiopyridine . . . "".",EXPIRED
63,WO,A1,WO 2021/097010 A1,045-871-129-422-703,2021-05-20,2021,US 2020/0060110 W,2020-11-12,US 201916686060 A,2019-11-15,SIMD OPERAND PERMUTATION WITH SELECTION FROM AMONG MULTIPLE REGISTERS,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers, In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/045-871-129-422-703,Patent Application,yes,3,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38,,0,0,,,,PENDING
64,US,A1,US 2021/0149679 A1,078-615-473-524-754,2021-05-20,2021,US 201916686060 A,2019-11-15,US 201916686060 A,2019-11-15,SIMD Operand Permutation with Selection from among Multiple Registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,APPLE INC (2019-11-14),https://lens.org/078-615-473-524-754,Patent Application,yes,0,3,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06T1/20;;G06T1/60,,0,0,,,,ACTIVE
65,US,B2,US 7354935 B2,109-017-875-610-404,2008-04-08,2008,US 52888803 A,2003-09-19,US 41322302 P;;US 0329707 W;;US 52888803 A,2002-09-24,Radiolabeled neurokinin-1 receptor antagonists,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/109-017-875-610-404,Granted Patent,yes,2,2,12,12,0,C07D401/12;;C07D401/12,A61K31/445;;A61K51/00;;C07D401/12,514/326;;546/201,2,0,,,"Database CAPLUS on STN (Columbus OH, USA) No. 1998:141375, Ding et al. ""probing the biochemical basis of the pet image,"" Abstract, Mar. 29, 1998.;;Database CAPLUS on STN (Columbus OH, USA) No. 1995: 924600, Ding et al. ""Mechanistic pet studies of F-18 labeled catecholamines in living baboon heart,"" Abstract, Aug. 20-24, 1995.",INACTIVE
66,EP,A4,EP 1545525 A4,042-878-911-017-76X,2009-07-01,2009,EP 03759348 A,2003-09-19,US 0329707 W;;US 41322302 P,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;126 EAST LINCOLN AVENUE, RAHWAY NEW JERSEY 07065 (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK  SHARP & DOHME CORP. (2012-10-19)",https://lens.org/042-878-911-017-76X,Search Report,no,1,0,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,3,3,035-422-421-942-320;;036-097-954-824-909;;034-798-247-244-066,10.1046/j.1471-4159.1995.65020682.x;;7616224;;10.1016/s0969-8051(00)00212-2;;11323237;;9228658;;10.1016/s0969-8051(97)00057-7,"DING YU-SHIN ET AL: ""Mechanistic positron emission tomography studies of 6-(18F)fluorodopamine in living baboon heart: Selective imaging and control of radiotracer metabolism using the deuterium isotope effect"", JOURNAL OF NEUROCHEMISTRY, vol. 65, no. 2, 1995, pages 682 - 690, XP002528289;;STALEY J K ET AL: ""Comparison of [<18>F]altanserin and [<18>F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies"", NUCLEAR MEDICINE AND BIOLOGY, vol. 28, no. 3, 2001, pages 271 - 279, XP004240675;;BONASERA T A ET AL: ""Retardation of 17-Oxidation of 16alpha-[<18>F]Fluoroestradiol-17beta by Substitution of Deuterium for Hydrogen in the 17alpha Position(6)"", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 3, 1997, pages 239 - 249, XP004073583",EXPIRED
67,GB,A,GB 2604497 A,000-750-883-776-470,2022-09-07,2022,GB 202206792 A,2020-11-12,US 201916686060 A;;US 2020/0060110 W,2019-11-15,SIMD operand permutation with selection from among multiple registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers, In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,CHRISTOPHER A BURNS;;LIANG-KAI WANG;;ROBERT D KENNEY;;TERENCE M POTTER,,https://lens.org/000-750-883-776-470,Patent Application,no,3,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38,,0,0,,,,ACTIVE
68,ZA,B,ZA 876207 B,161-675-647-422-751,1988-07-27,1988,ZA 876207 A,1987-08-21,AU PH760186 A,1986-08-22,MINEABLE DOWELS AND BOLTS,,AUSTRALIAN COAL IND RES,O'BEIRNE TERENCE JOHN;;TERENCE JOHN O'BEIRNE;;NAPPER ARTHUR;;ARTHUR NAPPER;;SHEPHERD JOHN;;JOHN SHEPHERD;;RIXON LABAN KEITH;;LABAN KEITH RIXON;;TAIT ROBERT BURNS;;ROBERT BURNS TAIT,,https://lens.org/161-675-647-422-751,Granted Patent,no,0,0,1,3,0,,E01D/,,0,0,,,,EXPIRED
69,EP,B1,EP 1545525 B1,022-384-442-055-548,2010-11-10,2010,EP 03759348 A,2003-09-19,US 0329707 W;;US 41322302 P,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK SHARP & DOHME,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;126 EAST LINCOLN AVENUE, RAHWAY NEW JERSEY 07065 (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK  SHARP & DOHME CORP. (2012-10-19)",https://lens.org/022-384-442-055-548,Granted Patent,yes,3,0,12,12,0,C07D401/12;;C07D401/12,A61K31/445;;A61K51/00;;C07D401/12,,5,0,,,"DING YU-SHIN ET AL: ""Mechanistic positron emission tomography studies of 6-(18F)fluorodopamine in living baboon heart: Selective imaging and control of radiotracer metabolism using the deuterium isotope effect"" JOURNAL OF NEUROCHEMISTRY, vol. 65, no. 2, 1995, pages 682-690, XP002528289;;STALEY J K ET AL: ""Comparison of [<18>F]altanserin and [<18>F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies"" NUCLEAR MEDICINE AND BIOLOGY, vol. 28, no. 3, 2001, pages 271-279, XP004240675;;BONASERA T A ET AL: ""Retardation of 17-Oxidation of 16alpha-[<18>F]Fluoroestradiol-17beta by Substitution of Deuterium for Hydrogen in the 17alpha Position(6)"" NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 3, 1997, pages 239-249, XP004073583;;DATABASE CAPLUS [Online] DING Y-S. ET AL.: 'Mechanistic pet studies of F-18 labeled catecholamines in living baboon heart: selective control of radiotracer metabolism using the deuterium isotope effect', XP002976956 Database accession no. 1995:924600 & BOOK OF ABSTRACTS, 210TH ACS NATIONAL MEETING, CHICAGO, IL no. PT.2, 20 August 1995,;;DATABASE CAPLUS [Online] DING Y-S. ET AL.: 'Probing the biochemical basis of the pet image', XP002976957 Database accession no. 1998:141375 & BOOK OF ABSTRACTS, 215TH ACS NATIONAL MEETING, DALLAS 29 March 1998,",EXPIRED
70,US,A1,US 2005/0214204 A1,011-915-242-867-921,2005-09-29,2005,US 52888803 A,2003-09-19,US 41322302 P;;US 0329707 W;;US 52888803 A,2002-09-24,Radiolabeled neurokinin-1 receptor antagonists,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/011-915-242-867-921,Patent Application,yes,1,4,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,424/1.11;;514/326;;546/210,0,0,,,,EXPIRED
71,US,A1,US 2021/0406031 A1,080-609-818-134-390,2021-12-30,2021,US 202117470682 A,2021-09-09,US 202117470682 A;;US 201916686060 A,2019-11-15,SIMD Operand Permutation with Selection from among Multiple Registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/080-609-818-134-390,Patent Application,yes,5,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06T1/20;;G06T1/60,,0,0,,,,ACTIVE
72,GB,B,GB 2604497 B,093-087-305-237-729,2023-10-04,2023,GB 202206792 A,2020-11-12,US 201916686060 A;;US 2020/0060110 W,2019-11-15,SIMD operand permutation with selection from among multiple registers,,APPLE INC,CHRISTOPHER A BURNS;;LIANG-KAI WANG;;ROBERT D KENNEY;;TERENCE M POTTER,,https://lens.org/093-087-305-237-729,Granted Patent,no,3,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06T1/20;;G06T1/60,,0,0,,,,ACTIVE
73,WO,A2,WO 2004/029024 A2,001-591-895-015-610,2004-04-08,2004,US 0329707 W,2003-09-19,US 41322302 P,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC;;BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,,https://lens.org/001-591-895-015-610,Patent Application,yes,0,4,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,0,0,,,,PENDING
74,CA,A1,CA 2499825 A1,049-111-665-709-154,2004-04-08,2004,CA 2499825 A,2003-09-19,US 41322302 P;;US 0329707 W,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,HAMILL TERENCE G;;ENG WAI-SI;;BURNS H DONALD;;GIBSON RAYMOND E,,https://lens.org/049-111-665-709-154,Patent Application,no,0,0,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,0,0,,,,EXPIRED
75,EP,A2,EP 1545525 A2,134-899-009-524-001,2005-06-29,2005,EP 03759348 A,2003-09-19,US 0329707 W;;US 41322302 P,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;126 EAST LINCOLN AVENUE, RAHWAY NEW JERSEY 07065 (2012-08-02);;SCHERING CORPORATION, US (2013-03-18);;MERCK  SHARP & DOHME CORP. (2012-10-19)",https://lens.org/134-899-009-524-001,Patent Application,yes,0,0,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,0,0,,,,EXPIRED
76,DE,D1,DE 60334922 D1,029-433-807-385-543,2010-12-23,2010,DE 60334922 T,2003-09-19,US 41322302 P;;US 0329707 W,2002-09-24,RADIOAKTIV MARKIERTE NEUROKININ-1-REZEPTOR-ANTAGONISTEN,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK SHARP & DOHME,BURNS DONALD H;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,"SCHERING CORPORATION, US (2012-12-13)",https://lens.org/029-433-807-385-543,Granted Patent,no,0,0,12,12,0,C07D401/12;;C07D401/12,A61K31/445;;A61K51/00;;C07D401/12,,0,0,,,,EXPIRED
77,CA,C,CA 2499825 C,127-354-231-542-83X,2011-11-01,2011,CA 2499825 A,2003-09-19,US 41322302 P;;US 0329707 W,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,"The present invention is directed to radiolabeled neurokinin-1 receptor antagonists of the formula: (See above formula) wherein: A is -CD2- or -CH2CH2-; or a pharmaceutically acceptable salt thereof, which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals; examples are [18F][2-fluorodideuteromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine, and pharmaceutically acceptable salts thereof; and [18F][3-fluoroethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine, and pharmaceutically acceptable salts thereof.",MERCK & CO INC,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,,https://lens.org/127-354-231-542-83X,Granted Patent,no,0,0,12,12,0,C07D401/12;;C07D401/12,C07D401/12;;A61K31/454;;A61K51/00,,0,0,,,,EXPIRED
78,US,B2,US 11645084 B2,121-680-584-871-706,2023-05-09,2023,US 202117470682 A,2021-09-09,US 202117470682 A;;US 201916686060 A,2019-11-15,SIMD operand permutation with selection from among multiple registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/121-680-584-871-706,Granted Patent,yes,19,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F15/80;;G06F9/30;;G06F9/38;;G06T1/20;;G06T1/60,,2,0,,,"International Search Report and Written Opinion in PCT Appl. No. PCT/US2020/060110 dated Feb. 25, 2021, 13 pages.;;Office Action in Chinese Appl. No. 202080079081.2 dated Dec. 14, 2022, 5 pages.",ACTIVE
79,DE,T5,DE 112020005617 T5,049-082-704-477-350,2022-09-08,2022,DE 112020005617 T,2020-11-12,US 201916686060 A;;US 2020/0060110 W,2019-11-15,SIMD-OPERAND PERMUTATION MIT AUSWAHL VON MEHREREN REGISTERN,"Es werden Techniken in Bezug auf Operand-Routing unter SIMD-Pipelines offenbart. In einigen Ausführungsformen schließt eine Einrichtung einen Satz mehrerer Hardware-Pipelines ein, die konfiguriert sind, um eine Single-Instruction-Multiple-Data-Anweisung (SIMD-Anweisung) für mehrere Threads parallel auszuführen, wobei die Anweisung erste und zweite Architekturregister angibt. In einigen Ausführungsformen schließen die Pipelines eine Ausführungsschaltlogik ein, die konfiguriert ist, um Operationen unter Verwendung einer oder mehrerer Pipelinesstufen der Pipeline durchzuführen. In einigen Ausführungsformen schließen die Pipelines eine Routingschaltlogik ein, die konfiguriert ist, um basierend auf der Anweisung einen ersten Eingabeoperanden für die Ausführungsschaltlogik von Folgendem auszuwählen: einen Wert aus dem ersten architektonischen Register aus dem threadspezifischen Speicher für eine andere Pipeline und einen Wert aus dem zweiten Architekturregister aus dem threadspezifischen Speicher für einen einer anderen Pipeline zugeordneten Thread. In einigen Ausführungsformen kann die Routingschaltlogik eine Verschiebe- und Füllanweisung unterstützen, die Speicherung eines beliebigen Abschnitts eines Grafikrahmens in einem oder mehreren Registern erleichtert.",APPLE INC,CHRISTOPHER A BURNS;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/049-082-704-477-350,Patent Application,no,0,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06F15/80;;G06T1/20,,0,0,,,,PENDING
80,CN,A,CN 116627504 A,095-900-900-366-981,2023-08-22,2023,CN 202310602114 A,2020-11-12,CN 202310602114 A;;CN 202080079081 A;;US 201916686060 A;;US 2020/0060110 W,2019-11-15,SIMD operand arrangement selected from multiple registers,"The invention relates to a SIMD operand arrangement selected from a plurality of registers. In some implementations, an apparatus includes a set of multiple hardware pipelines configured to execute in parallel single instruction multiple data (SIMD) instructions for multiple threads, the instructions specifying first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, these pipelines include routing circuitry, and a processor configured to select, based on the instruction, a first input operand for the execution circuitry from a value of the first architectural register from a thread-specific storage of another pipeline and a value of the second architectural register from a thread-specific storage assigned to a thread of another pipeline. The routing circuitry may support shift and fill instructions that facilitate storage of any portion of the graphics frame in one or more registers.",APPLE INC,C A BURNS;;WANG LIANG-KAI;;KENNY ROBERT D;;POTTER TERENCE M,,https://lens.org/095-900-900-366-981,Patent Application,no,6,1,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38,,0,0,,,,ACTIVE
81,US,A1,US 2023/0325196 A1,137-074-271-727-034,2023-10-12,2023,US 202318299452 A,2023-04-12,US 202318299452 A;;US 202117470682 A;;US 201916686060 A,2019-11-15,SIMD Operand Permutation with Selection from among Multiple Registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/137-074-271-727-034,Patent Application,yes,0,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06T1/20;;G06T1/60,,0,0,,,,PENDING
82,CN,A,CN 114830082 A,186-870-413-527-447,2022-07-29,2022,CN 202080079081 A,2020-11-12,US 201916686060 A;;US 2020/0060110 W,2019-11-15,SIMD operand arrangement selected from multiple registers,"Techniques related to operand routing between SIMD pipelines are disclosed. In some implementations, an apparatus includes a set of multiple hardware pipelines configured to execute in parallel a single instruction multiple data (SIMD) instruction for multiple threads, where the instruction specifies a first architectural register and a second architectural register. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, these pipelines include routing circuitry, the routing circuitry is configured to select, based on the instruction, a first input operand for the execution circuitry from a value of the first architectural register from a thread-specific storage of another pipeline and a value of the second architectural register from a thread-specific storage assigned to a thread of another pipeline. In some embodiments, the routing circuitry may support shift and padding instructions that facilitate storage of any portion of the graphics frame in one or more registers.",APPLE INC,C A BURNS;;WANG LIANG-KAI;;KENNY ROBERT D;;POTTER TERENCE M,,https://lens.org/186-870-413-527-447,Patent Application,no,5,1,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38,,0,0,,,,ACTIVE
83,US,B2,US 11126439 B2,142-368-430-608-388,2021-09-21,2021,US 201916686060 A,2019-11-15,US 201916686060 A,2019-11-15,SIMD operand permutation with selection from among multiple registers,"Techniques are disclosed relating to operand routing among SIMD pipelines. In some embodiments, an apparatus includes a set of multiple hardware pipelines configured to execute a single-instruction multiple-data (SIMD) instruction for multiple threads in parallel, wherein the instruction specifies first and second architectural registers. In some embodiments, the pipelines include execution circuitry configured to perform operations using one or more pipeline stages of the pipeline. In some embodiments, the pipelines include routing circuitry configured to select, based on the instruction, a first input operand for the execution circuitry from among: a value from the first architectural register from thread-specific storage for another pipeline and a value from the second architectural register from thread-specific storage for a thread assigned to another pipeline. In some embodiments, the routing circuitry may support a shift and fill instruction that facilitates storage of an arbitrary portion of a graphics frame in one or more registers.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG-KAI;;KENNEY ROBERT D;;POTTER TERENCE M,APPLE INC (2019-11-14),https://lens.org/142-368-430-608-388,Granted Patent,yes,15,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F15/80;;G06F9/30;;G06F9/38;;G06T1/20;;G06T1/60,,1,0,,,"International Search Report and Written Opinion in PCT Appl. No. PCT/US2020/060110 dated Feb. 25, 2021, 13 pages.",ACTIVE
84,WO,A1,WO 2006/061552 A1,040-021-151-550-83X,2006-06-15,2006,GB 2005004026 W,2005-10-18,GB 0427151 D,2004-12-11,METHOD FOR THE CO-PRODUCTION OF OLEFINS AND GTL PRODUCTS,"The present invention provides a method for the co-production of product streams comprising hydrocarbons boiling in the diesel range and olefins, said method comprising: (a) providing a Gas-to-Liquids (GTL) process and an autothermal cracking (ATC) process, said GTL process comprising a reforming reactor and a Fischer-Tropsch (FT) reactor, (b) reforming a methane-containing feed stream in said reforming reactor to produce a first reactant stream comprising synthesis gas, (c) reacting the first reactant stream comprising synthesis gas in said FT reactor to produce a product stream comprising hydrocarbons, (d) treating the product stream comprising hydrocarbons to produce a first product stream comprising ethane and propane, and a second product stream comprising hydrocarbons boiling in the diesel range, (e) feeding the first product stream comprising ethane and propane to said autothermal cracking process, wherein said first product stream reacts with a molecular oxygen&shy;containing gas in the presence of a catalyst to produce a product stream comprising olefins and synthesis gas, ( f ) treating the product stream comprising olefins and synthesis gas to separate a second reactant stream comprising synthesis gas and a product stream comprising olefins, and (g) feeding the second reactant stream comprising synthesis gas to the reformer of step (b) or to the Fischer-Tropsch reactor of step (c), wherein said autothermal cracking process shares one or more process facilities with the GTL process.",INNOVENE EUROP LTD;;BELL PETER SIMPSON;;BURNS ANDREW LINDSEY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,BELL PETER SIMPSON;;BURNS ANDREW LINDSEY;;GRIFFITHS DAVID CHARLES;;WOODFIN WILLIAM TERENCE,,https://lens.org/040-021-151-550-83X,Patent Application,yes,5,5,1,1,0,C10G11/22;;C01B3/38;;C01B3/386;;C01B2203/0233;;C01B2203/0261;;C01B2203/0283;;C01B2203/0415;;C01B2203/046;;C01B2203/0475;;C01B2203/062;;C01B2203/1047;;C01B2203/1058;;C01B2203/1064;;C01B2203/107;;C01B2203/1088;;C01B2203/1094;;C01B2203/1241;;C01B2203/1247;;C01B2203/142;;C01B2203/84;;C07C4/025;;C07C11/02;;C07C2523/40;;C07C2523/74;;C10G2/32;;C10G2400/20;;Y02P30/40,C10G2/00;;C07C1/04;;C10G9/38,,2,2,062-725-387-704-923;;037-407-384-353-291,10.1002/0471238961.1618150308011212.a01;;10.1002/0471238961.1612011413050919.a01,"NICK HALLALE: ""Kirk-Othmer Encyclopedia of Chemical Technology - Process Integration Technology"", 17 May 2002, JOHN WILEY & SONS, ONLINE, XP002359334;;ROLAND E. MEISSNER: ""Kirk-Othmer Encyclopedia of Chemical Technology - Plant Layout (Archive)"", 4 December 2000, JOHN WILEY & SONS, ONLINE, XP002359335",PENDING
85,GB,A,GB 2621255 A,142-831-334-274-316,2024-02-07,2024,GB 202311894 A,2020-11-12,US 201916686060 A;;GB 202206792 A,2019-11-15,SIMD operand permutation with selection from among multiple registers,"A set of multiple hardware pipelines configured to: store data for a first portion of a graphics frame in a first architectural register, including storing values for respective threads of a single-instruction multiple-data (SIMD) group in thread-specific versions of the first architectural register; store data for a second portion of a graphics frame in a second architectural register, including storing values for respective threads of a SIMD group in thread-specific versions of the second architectural register; execute via routing circuitry an instruction which stores a proper subset of the thread-specific versions of both the first and second architectural registers in thread-specific version of a third architectural register, wherein the storage of the proper sub-sets moves values from thread-specific versions of the first and second architectural registers to other threads versions of the third architectural register. The proper sub-sets may be contiguous groups of threads, and wherein the instruction is a shift and fill instruction that specifies a number of threads for the movement. Image filtering operations based on pixel data stored in the third register can be performed.",APPLE INC,CHRISTOPHER A BURNS;;LIANG-KAI WANG;;ROBERT D KENNEY;;TERENCE M POTTER,,https://lens.org/142-831-334-274-316,Patent Application,no,1,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/30;;G06F9/38;;G06T1/20;;G06T1/60,,0,0,,,,PENDING
86,KR,A,KR 20220074969 A,181-237-413-160-598,2022-06-03,2022,KR 20227015984 A,2020-11-12,US 201916686060 A;;US 2020/0060110 W,2019-11-15,다수의 레지스터들 중에서의 선택을 이용한 SIMD 피연산자 순열,"SIMD 파이프라인들 사이의 피연산자 라우팅과 관련된 기법들이 개시된다. 일부 실시예들에서, 장치는, 다수의 스레드들에 대한 단일 명령어 다중 데이터(SIMD) 명령어를 병렬로 실행하도록 구성되는 다수의 하드웨어 파이프라인들의 세트를 포함하고, 명령어는 제1 및 제2 아키텍처 레지스터들을 특정한다. 일부 실시예들에서, 파이프라인들은 파이프라인의 하나 이상의 파이프라인 스테이지들을 사용하여 동작들을 수행하도록 구성되는 실행 회로부를 포함한다. 일부 실시예들에서, 파이프라인들은, 명령어에 기초하여, 다른 파이프라인에 대한 스레드 특정 저장소로부터 제1 아키텍처 레지스터로부터의 값 및 다른 파이프라인에 할당된 스레드에 대한 스레드 특정 저장소로부터 제2 아키텍처 레지스터로부터의 값 중에서, 실행 회로부에 대한 제1 입력 피연산자를 선택하도록 구성되는 라우팅 회로부를 포함한다. 일부 실시예들에서, 라우팅 회로부는 하나 이상의 레지스터들에서 그래픽 프레임의 임의의 부분의 저장을 용이하게 하는 시프트 및 채움 명령어를 지원할 수 있다.",APPLE INC,BURNS CHRISTOPHER A;;WANG LIANG KAI;;KENNEY ROBERT D;;POTTER TERENCE M,,https://lens.org/181-237-413-160-598,Patent Application,no,0,0,16,16,0,G06F9/3887;;G06F9/3887;;G06F9/3828;;G06F9/3851;;G06F9/3828;;G06F9/3851;;G06F9/3887;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/3887;;G06F9/3851;;G06F9/3828;;G06F9/30098;;G06T1/20;;G06T1/60;;G06F9/30098;;G06F9/3887;;G06T1/20;;G06T1/60,G06F9/38;;G06F9/30;;G06T1/20;;G06T1/60,,0,0,,,,PENDING
87,WO,A3,WO 2004/029024 A3,108-876-859-434-446,2004-07-08,2004,US 0329707 W,2003-09-19,US 41322302 P,2002-09-24,RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS,The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.,MERCK & CO INC;;BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,BURNS H DONALD;;ENG WAI-SI;;GIBSON RAYMOND E;;HAMILL TERENCE G,,https://lens.org/108-876-859-434-446,Search Report,yes,2,0,12,12,0,C07D401/12;;C07D401/12,A61K51/00;;C07D401/12,,2,1,035-422-421-942-320,10.1046/j.1471-4159.1995.65020682.x;;7616224,"DATABASE CAPLUS [online] DING Y-S. ET AL.: ""Mechanistic pet studies of F-18 labeled catecholamines in living baboon heart: selective control of radiotracer metabolism using the deuterium isotope effect"", XP002976956, Database accession no. 1995:924600;;DATABASE CAPLUS [online] DING Y-S. ET AL.: ""Probing the biochemical basis of the pet image"", XP002976957, Database accession no. 1998:141375",PENDING
88,AU,A,AU 1987/077270 A,041-141-007-063-247,1988-02-25,1988,AU 1987/077270 A,1986-08-22,AU 1987/077270 A,1986-08-22,ROCK ANCHOR OF PLASTICS MATERIAL,,AUSTRALIAN COAL IND RES,O'BEIRNE TERENCE JOHN;;SHEPHERD JOHN;;NAPPER ARTHUR;;RIXON LABAN KEITH;;TAIT ROBERT BURNS,,https://lens.org/041-141-007-063-247,Patent Application,no,0,2,1,1,0,,E21D20/02,,0,0,,,,DISCONTINUED
89,AU,A,AU 1987/077323 A,180-828-887-952-595,1988-02-25,1988,AU 1987/077323 A,1987-08-21,AU 1987/077323 A;;AU PH760286 A,1986-08-22,MINE WALL STRAP AND LINER SYSTEMS,,AUSTRALIAN COAL INDUSTRY RES LABORATORIES LIMITED,O'BEIRNE TERENCE JOHN;;NAPPER ARTHUR;;TAIT ROBERT BURNS;;SHEPHERD JOHN;;RIXON LABAN KEITH,,https://lens.org/180-828-887-952-595,Patent Application,no,0,0,2,2,0,E21D11/152,E21D11/00;;E21D11/15;;E21D19/04;;E21D21/00,,0,0,,,,EXPIRED
90,AU,B2,AU 592218 B2,076-620-726-864-970,1990-01-04,1990,AU 1987/077323 A,1987-08-21,AU 1987/077323 A;;AU PH760286 A,1986-08-22,MINE RIB OR WALL SUPPORT,,AUSTRALIAN COAL IND RES,O'BEIRNE TERENCE JOHN;;NAPPER ARTHUR;;TAIT ROBERT BURNS;;SHEPHERD JOHN;;RIXON LABAN KEITH,,https://lens.org/076-620-726-864-970,Granted Patent,no,0,0,2,2,0,E21D11/152,E21D11/00;;E21D11/15;;E21D19/04;;E21D21/00,,0,0,,,,EXPIRED
91,DE,T2,DE 69434339 T2,180-663-055-545-521,2006-03-09,2006,DE 69434339 T,1994-10-21,US 14203793 A,1993-10-28,Druckfarben zum Mehrfarbendruck,,LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,,https://lens.org/180-663-055-545-521,Granted Patent,no,0,0,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
92,DE,D1,DE 69434339 D1,011-390-065-739-267,2005-05-25,2005,DE 69434339 T,1994-10-21,US 14203793 A,1993-10-28,Druckfarben zum Mehrfarbendruck,,LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,,https://lens.org/011-390-065-739-267,Granted Patent,no,0,0,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
93,EP,B1,EP 0651036 B1,019-147-747-676-217,2005-04-20,2005,EP 94307762 A,1994-10-21,US 14203793 A,1993-10-28,Inks used in multi-color printing,,LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,"FUNAI ELECTRIC CO., LTD, JP (2013-11-07);;FUNAI ELECTRIC CO., LTD, DAITO CITY, JP (2013-11-07)",https://lens.org/019-147-747-676-217,Granted Patent,yes,3,0,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
94,EP,A2,EP 0651036 A2,140-856-458-526-202,1995-05-03,1995,EP 94307762 A,1994-10-21,US 14203793 A,1993-10-28,Inks used in multi-color printing.,"Aqueous inks containing 1,2-alkyl of from C4 to C10 diols, specifically 1,2-hexanediol or 1,2-pentanediol are employed in jet inks. Two such inks of different colors applied side-by-side to paper do not bleed and therefore give excellent image definition. The diols are not flammable, odorous or highly volatile.",LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,"FUNAI ELECTRIC CO., LTD, JP (2013-11-07);;FUNAI ELECTRIC CO., LTD, DAITO CITY, JP (2013-11-07)",https://lens.org/140-856-458-526-202,Patent Application,yes,0,3,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
95,BR,A,BR 9404278 A,147-780-198-022-580,1995-07-04,1995,BR 9404278 A,1994-10-27,US 14203793 A,1993-10-28,Tintas para impressão a jato de tinta e processo de impressão multicolorida,,LEXMARK INT INC,BEACH BRADLEY LEONARD;;BURNS KATHRYN ELIZABETH;;FRANEY TERENCE EDWARD;;PIEKUNKA ANN MARIE;;SPIVEY PAUL TIMOTHY;;ZIMMER AGNES KAM,FUNAI ELECTRIC COMPANY LTD (JP) (2014-03-11),https://lens.org/147-780-198-022-580,Patent Application,no,0,0,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
96,US,A,US 5364461 A,140-371-492-241-045,1994-11-15,1994,US 14203793 A,1993-10-28,US 14203793 A,1993-10-28,Inks used in multi-color printing,"Aqueous inks containing 1,2-alkyl of from C4 to C10 diols, specifically 1,2-hexanediol or 1,2-pentanediol are employed in jet inks. Two such inks of different colors applied side-by-side to paper do not bleed and therefore give excellent image definition. The diols are not flammable, odorous or highly volatile.",LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,LEXMARK INTERNATIONAL INC (1993-10-26);;FUNAI ELECTRIC CO. LTD (2013-04-01),https://lens.org/140-371-492-241-045,Granted Patent,yes,8,49,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,106 22R;;X106 20D,0,0,,,,EXPIRED
97,EP,A3,EP 0651036 A3,073-128-804-536-646,1995-11-29,1995,EP 94307762 A,1994-10-21,US 14203793 A,1993-10-28,Inks used in multi-color printing.,"Aqueous inks containing 1,2-alkyl of from C4 to C10 diols, specifically 1,2-hexanediol or 1,2-pentanediol are employed in jet inks. Two such inks of different colors applied side-by-side to paper do not bleed and therefore give excellent image definition. The diols are not flammable, odorous or highly volatile.",LEXMARK INT INC,BEACH BRADLEY L;;BURNS KATHRYN E;;FRANEY TERENCE E;;PIEKUNKA ANN M;;SPIVEY PAUL T;;ZIMMER AGNES K,"FUNAI ELECTRIC CO., LTD, JP (2013-11-07);;FUNAI ELECTRIC CO., LTD, DAITO CITY, JP (2013-11-07)",https://lens.org/073-128-804-536-646,Search Report,yes,3,0,10,10,0,C09D11/30;;C09D11/40;;C09D11/38;;B41M5/00;;C09D11/30;;C09D11/40,C09D11/00,,0,0,,,,EXPIRED
98,US,A1,US 2017/0293470 A1,177-405-562-899-148,2017-10-12,2017,US 201615092401 A,2016-04-06,US 201615092401 A,2016-04-06,Floating-Point Multiply-Add with Down-Conversion,"Techniques are disclosed relating to floating-point operations with down-conversion. In some embodiments, a floating-point unit is configured to perform fused multiply-addition operations based on first and second different instruction types. In some embodiments, the first instruction type specifies result in the first floating-point format and the second instruction type specifies fused multiply addition of input operands in the first floating-point format to generate a result in a second, lower-precision floating-point format. For example, the first format may be a 32-bit format and the second format may be a 16-bit format. In some embodiments, the floating-point unit includes rounding circuitry, exponent circuitry, and/or increment circuitry configured to generate signals for the second instruction type in the same pipeline stage as for the first instruction type. In some embodiments, disclosed techniques may reduce the number of pipeline stages included in the floating-point circuitry.",APPLE INC,WANG LIANG-KAI;;POTTER TERENCE M;;HAVLIR ANDREW M;;SUN YU;;PENA NICOLAS X;;WU XIAO-LONG;;BURNS CHRISTOPHER A,APPLE INC (2016-03-31),https://lens.org/177-405-562-899-148,Patent Application,yes,1,11,2,2,0,G06F7/483;;G06F7/483;;G06F7/5443;;G06F7/5443,G06F7/483,,0,0,,,,ACTIVE
99,US,B2,US 10282169 B2,152-922-220-409-960,2019-05-07,2019,US 201615092401 A,2016-04-06,US 201615092401 A,2016-04-06,Floating-point multiply-add with down-conversion,"Techniques are disclosed relating to floating-point operations with down-conversion. In some embodiments, a floating-point unit is configured to perform fused multiply-addition operations based on first and second different instruction types. In some embodiments, the first instruction type specifies result in the first floating-point format and the second instruction type specifies fused multiply addition of input operands in the first floating-point format to generate a result in a second, lower-precision floating-point format. For example, the first format may be a 32-bit format and the second format may be a 16-bit format. In some embodiments, the floating-point unit includes rounding circuitry, exponent circuitry, and/or increment circuitry configured to generate signals for the second instruction type in the same pipeline stage as for the first instruction type. In some embodiments, disclosed techniques may reduce the number of pipeline stages included in the floating-point circuitry.",APPLE INC,WANG LIANG-KAI;;POTTER TERENCE M;;HAVLIR ANDREW M;;SUN YU;;PENA NICOLAS X;;WU XIAO-LONG;;BURNS CHRISTOPHER A,APPLE INC (2016-03-31),https://lens.org/152-922-220-409-960,Granted Patent,yes,6,2,2,2,0,G06F7/483;;G06F7/483;;G06F7/5443;;G06F7/5443,G06F7/483;;G06F7/544,,0,0,,,,ACTIVE
100,EP,A4,EP 1641493 A4,011-582-182-696-40X,2007-10-31,2007,EP 04777002 A,2004-06-25,US 2004/0020233 W;;US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,,MERCK & CO INC,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP. (2010-03-10),https://lens.org/011-582-182-696-40X,Search Report,no,4,0,7,51,0,A61K51/0406;;A61K51/0455;;A61K51/0459;;C07D213/64;;C07D239/34;;A61P43/00;;C07D213/64;;A61K51/0406;;A61K51/0455;;C07D239/34;;A61K51/0459,A61K51/00;;A61K51/04;;A61P43/00;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,1,0,,,See also references of WO 2005009479A1,DISCONTINUED
101,CA,A1,CA 2530087 A1,066-130-235-458-56X,2005-02-03,2005,CA 2530087 A,2004-06-25,US 48367903 P;;US 2004/0020233 W,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly human s. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the process es for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds a re described.",MERCK & CO INC,BURNS DONALD H;;JEWELL JAMES P;;CHEN ALEX M;;GIBSON RAYMOND E;;LIU PING;;LIN LINUS S;;PERESYPKIN ANDREY V;;GOULET MARK T;;HAMILL TERENCE G;;HAGMANN WILLIAM K,,https://lens.org/066-130-235-458-56X,Patent Application,no,0,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,0,0,,,,DISCONTINUED
102,US,B2,US 7754188 B2,121-686-170-103-43X,2010-07-13,2010,US 55922805 A,2005-12-06,US 55922805 A;;US 48367903 P;;US 2004/0020233 W,2003-06-30,Radiolabeled cannabinoid-1 receptor modulators,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",MERCK SHARP & DOHME,BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP (2004-06-11),https://lens.org/121-686-170-103-43X,Granted Patent,yes,8,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;A61M36/14;;C07D213/64;;C07D239/34,424/1.65;;424/1.89,19,18,002-118-695-260-745;;011-418-238-237-321;;115-417-042-272-156;;045-379-519-499-488;;075-637-625-973-259;;030-454-957-682-912;;031-687-469-317-821;;016-837-993-239-724;;000-574-072-545-759;;000-502-354-909-597;;031-104-756-448-392;;134-695-829-186-779;;119-499-508-900-220;;063-249-756-032-037;;102-346-375-032-09X;;002-023-701-824-040;;159-805-998-770-580;;077-500-131-116-893,10.1021/jm020157x;;12570386;;12234592;;10.1016/s0969-8051(02)00308-6;;11150708;;10.1016/s0969-8051(00)00152-9;;10.1016/s0009-3084(02)00148-2;;12505691;;10.1002/(sici)1099-1344(199906)42:6<589::aid-jlcr219>3.3.co;2-2;;9422389;;10.1046/j.1471-4159.1998.70010417.x;;10.1517/13543776.10.10.1529;;10.1016/s0165-6147(00)01482-6;;10838609;;10.1517/13543776.8.3.301;;10.1016/j.bmcl.2004.03.034;;15109619;;15110734;;10.1016/j.biopsych.2004.01.005;;10.1002/(sici)1099-1344(199610)38:10<875::aid-jlcr908>3.3.co;2-7;;10.1002/jlcr.647;;10.1002/jlcr.720;;15878505;;10.1016/j.nucmedbio.2005.02.007;;10.1021/jm050135l;;16190764;;10.1016/s0065-7743(08)60582-5;;16596783;;10.1007/3-540-26573-2_14,"Katoch-Rouse et al., J. Med. Chem., vol. 46 (2003), pp. 642-645, ""Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: . . . "".;;Mathews et al., Nuclear Med. & Biol., vol. 29 (2002), pp. 671-677, ""Carbon-11 labeled radioligands for imaging brain cannabinoid receptors"".;;Mathews et al., Nuclear Med. & Biol., vol. 27 (2000), pp. 757-762, ""Biodistribution of [18F] SR144385 and [18F] SR147963: . . . "".;;Gifford et al., Chem. and Physics of Lipids, vol. 121 (2002), pp. 65-72, ""In vivo imaging of the rain cannabinoid receptor"".;;Mathews et al., J. of Labelled Compounds and Radiopharm., vol. 42 (1999), pp. 589-596, ""Synthesis of [18F] SR144385: . . . "".;;Gatley et al., J. of Neurochem., vol. 70 (1998), pp. 417-423, ""Imaging the brain marijuana receptor: . . . "".;;Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, ""Recent advances in cannabinoid receptor agonists and antagonists"".;;Piomelli et al., TiPS, vol. 21 (2000), pp. 218-224, ""The endocannabinoid system as a target for therapeutic drugs"".;;Barth, Exp. Opin. Ther. Patent, Vo. 8 (1998), pp. 301-313, ""Cannabinoid receptor agonists and antagonists"".;;Kumar et al., Bioorgan. & Med. Chem. Letters, vol. 14 (2004), pp. 2393-2396, ""Synthesis of [O-methyl-11C]1-(2-chloropheny1)-5-(4-methoxypheny1)-4-methyl-1H-pyrazole-3-carboxylic acid . . . "".;;Berding et al., Biol. Psychiatry, vol. 55 (2004), pp. 904-915, ""[123]AM281 Single-photon emission computed tomography imaging of cnetral cannabinoid CB1 receptors before and after delta9-tetrahydrocannabinool . . . "".;;Lan et al., J. of Labelled Compounds and Radiopharm., vol. 38 (1996), pp. 875-881, ""Preparation of iodine-123 labeled AM251: . . . "".;;Katoch-Rouse et al., J.of Labelled Compounds and Radiopharm., vol. 46 (2003), pp. 93-98, ""Synthesis of N-(piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2-chloropheny1)-4[18F]fluoro-1H-pyrazole-3-carboxamide . . . "".;;Willis et al, J. of Labelled Compounds and Radiopharm., vol. 46 (2003), pp. 799-804, ""Regioselective F-18 radiolabeling of AM694, a CB1 cannabinoid receptor ligand"".;;Li et al., Nuclear Med. & Biol., vol. 32 (2005), pp. 361-366, ""Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds"".;;Deng et al., J. Med. Chem., vol. 48 (2005), pp. 6386-6392, ""Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor"".;;Xiang et al., Ann. Reports in Med. Chem., vol. 34 (1999), pp. 199-208, ""Chapt. 20. Pharmacology of cannabinoid receptor agonists and antagonists"".;;Mason et al., Ann. Reports in Med. Chem., vol. 40 (2005), pp. 49-61, ""Positron emission tomography agents for central nervous system drug development applications"".;;Lindsey et al., Handbook of Exp. Pharmacol., vol. 168 (2005), pp. 425-443, ""Imaging of the Brain Cannabinoid System"".",INACTIVE
103,EP,A1,EP 1641493 A1,019-291-561-272-587,2006-04-05,2006,EP 04777002 A,2004-06-25,US 2004/0020233 W;;US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,,MERCK & CO INC,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP. (2010-03-10),https://lens.org/019-291-561-272-587,Patent Application,yes,0,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;A61P43/00;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,0,0,,,,DISCONTINUED
104,WO,A1,WO 2005/009479 A1,045-001-089-417-088,2005-02-03,2005,US 2004/0020233 W,2004-06-25,US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",MERCK & CO INC;;BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,,https://lens.org/045-001-089-417-088,Patent Application,yes,1,24,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/04;;C07D213/64;;C07D239/34,,1,0,,,See also references of EP 1641493A4,PENDING
105,US,A1,US 2006/0115425 A1,055-744-009-762-27X,2006-06-01,2006,US 55922805 A,2005-12-06,US 55922805 A;;US 48367903 P;;US 2004/0020233 W,2003-06-30,Substituted amides,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP (2004-06-11),https://lens.org/055-744-009-762-27X,Patent Application,yes,5,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;C07D213/64;;C07D213/70;;C07D239/34,424/1.11;;534/11;;546/290,0,0,,,,INACTIVE
106,US,A1,US 2007/0060618 A1,112-127-457-872-247,2007-03-15,2007,US 53263403 A,2003-10-24,US 53263403 A;;US 42080902 P;;US 0333613 W,2002-10-24,Alkyne derivatives as tracers for metabotropic glutamate receptor binding,"The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11 C, 13 C, 14 C, 18 F, 15 O, 13 N, 35 S, 2 H, and 3 H labeled compounds. In particular, the present invention is directed to 11 C, 13 C, 14 C, 18 F, 15 O, 13 N, 35 S, 2 H, and 3 H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11 C, 18 F, 15 O, or 13 N labeled heterocyclic alkyne compounds as tracers in positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).",MERCK & CO INC,COSFORD NICHOLAS DAVID P;;GOVCK STEVEN P;;HAMILL TERENCE G;;KAMENECKA THEODORE;;SEIDERS THOMAS J;;ROPPE JEFFREY R;;BONNEFOUS CELINE;;BURNS DONALD;;BRAUN MATTHEW P;;DEAN DENNIS C;;SIMEONE JOSEPH P,MERCK & CO. INC (2004-01-15),https://lens.org/112-127-457-872-247,Patent Application,yes,6,22,8,8,0,A61K51/04;;A61K51/0453;;A61K51/0455;;C07B2200/05;;C07D213/22;;C07D213/65;;C07D277/30;;C07D417/06;;C07D417/14;;A61P35/00;;C07D417/14;;A61K51/0455;;C07D213/22;;C07D417/06;;A61K51/04;;A61K51/0453;;C07D277/30;;C07D213/65;;C07B2200/05,A61K31/444;;A61K31/426;;A61K31/4439;;A61K51/00;;A61K51/04;;A61P35/00;;C07D213/22;;C07D213/65;;C07D277/30;;C07D417/06;;C07D417/14,514/332;;514/342;;514/369;;546/255;;546/256;;546/269.7;;548/201,0,0,,,,DISCONTINUED
107,EP,A2,EP 1556142 A2,171-713-458-002-376,2005-07-27,2005,EP 03779188 A,2003-10-24,US 0333613 W;;US 42080902 P,2002-10-24,ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING,,MERCK & CO INC,COSFORD NICHOLAS DAVID PETER;;GOVEK STEVEN PATRICK;;HAMILL TERENCE GERARD;;KAMENECKA THEODORE;;ROPPE JEFFREY ROGER;;SEIDERS THOMAS JONATHAN;;SIMEONE JOSEPH PAUL;;DEAN DENNIS C;;BRAUN MATTHEW P;;BONNEFOUS CELINE;;BURNS DONALD,,https://lens.org/171-713-458-002-376,Patent Application,yes,0,0,8,8,0,A61K51/04;;A61K51/0453;;A61K51/0455;;C07B2200/05;;C07D213/22;;C07D213/65;;C07D277/30;;C07D417/06;;C07D417/14;;A61P35/00;;C07D417/14;;A61K51/0455;;C07D213/22;;C07D417/06;;A61K51/04;;A61K51/0453;;C07D277/30;;C07D213/65;;C07B2200/05,C07D213/22;;A61K31/425;;A61K31/44;;A61K51/04;;A61P35/00;;C07D213/62;;C07D213/65;;C07D277/20;;C07D277/30;;C07D417/00;;C07D417/06;;C07D417/14,,0,0,,,,DISCONTINUED
108,CA,A1,CA 2503245 A1,080-021-109-310-139,2004-05-06,2004,CA 2503245 A,2003-10-24,US 42080902 P;;US 0333613 W,2002-10-24,ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING,"The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C,14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled compounds. In particular, the present invention is directed to 11C, 13C, 14C , 18F, 15O, 13N, 35S, 2H, and 3H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11C, 18F, 15O, or 13N labeled heterocyclic alkyne compounds as tracers i n positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).",MERCK & CO INC,KAMENECKA THEODORE;;ROPPE JEFFREY ROGER;;SEIDERS THOMAS JONATHAN;;COSFORD NICHOLAS DAVID PETER;;GOVEK STEVEN PATRICK;;HAMILL TERENCE GERARD;;BURNS DONALD;;BONNEFOUS CELINE;;DEAN DENNIS C;;BRAUN MATTHEW P;;SIMEONE JOSEPH PAUL,,https://lens.org/080-021-109-310-139,Patent Application,no,0,0,8,8,0,A61K51/04;;A61K51/0453;;A61K51/0455;;C07B2200/05;;C07D213/22;;C07D213/65;;C07D277/30;;C07D417/06;;C07D417/14;;A61P35/00;;C07D417/14;;A61K51/0455;;C07D213/22;;C07D417/06;;A61K51/04;;A61K51/0453;;C07D277/30;;C07D213/65;;C07B2200/05,A61K51/04;;A61P35/00;;C07D213/22;;C07D213/65;;C07D277/30;;C07D417/06;;C07D417/14,,0,0,,,,DISCONTINUED
